CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
“As we continue to make meaningful progress with the nation's largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,” said Brian Carrico, CEO of NeurAxis. “We continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT code, together with the inclusion of our PENFS technology in leading clinical guidelines, is reinforcing IB-Stim's clinical and economic value among payers. Supported by a strong balance sheet, we are well positioned to expand our commercial organization as reimbursement coverage grows and demand for IB-Stim continues to increase.”
NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit
http://neuraxis.com
.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precautions, warnings, and IFU, please see:
https://ibstim.com/important-information/
.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
View the Zacks #1 Rank List
NeurAxis Announces Additional Mid-Atlantic Coverage for IB-Stim PENFS Therapy, Expanding Access to Over 500,000 Lives
NeurAxis expands PENFS coverage for over 500,000 lives, enhancing access to its IB-Stim treatment for abdominal pain disorders.
Quiver AI Summary
NeurAxis, Inc. announced an expansion of medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, which will enhance access for over 500,000 patients in the Mid-Atlantic region. CEO Brian Carrico emphasized the importance of this coverage in broadening patient access and reinforcing reimbursement efforts alongside the introduction of a new Category I CPT code. IB-Stim is FDA-cleared for treating functional abdominal pain related to irritable bowel syndrome (IBS) and functional dyspepsia in patients aged 8 and older, addressing a significant gap as there are currently no FDA-approved drug therapies for pediatric patients with such conditions. NeurAxis continues to focus on advancing IB-Stim through evidence-based medicine while expectations for future trials and market expansion remain optimistic.
Potential Positives
Potential Negatives
FAQ
What is NeurAxis, Inc. known for?
NeurAxis, Inc. specializes in neuromodulation therapies for chronic conditions in children and adults, particularly with its IB-Stim technology.
What is the significance of new medical policy coverage?
The new medical policy coverage for PENFS expands access to IB-Stim treatment for over 500,000 patients in the Mid-Atlantic region.
What conditions does IB-Stim treat?
IB-Stim is FDA-cleared for treating functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia in patients aged 8 and older.
How does IB-Stim work?
IB-Stim is a non-invasive device that stimulates cranial nerve bundles in the ear to regulate pain signaling between the gut and brain.
What are the future plans for NeurAxis?
NeurAxis plans to expand its commercial organization and conduct additional clinical trials for PENFS in conditions with significant unmet healthcare needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NRXS Insider Trading Activity
$NRXS insiders have traded $NRXS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NRXS stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NRXS Hedge Fund Activity
We have seen 13 institutional investors add shares of $NRXS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.
“As we continue to make meaningful progress with the nation's largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement network,” said Brian Carrico, CEO of NeurAxis. “We continue to build momentum toward comprehensive nationwide written policy coverage for IB-Stim. The implementation of the Category I CPT code, together with the inclusion of our PENFS technology in leading clinical guidelines, is reinforcing IB-Stim's clinical and economic value among payers. Supported by a strong balance sheet, we are well positioned to expand our commercial organization as reimbursement coverage grows and demand for IB-Stim continues to increase.”
NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com .
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/ .
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
Read full article here »